ARMSTRONG, A. W.; PAPP, K. A.; ZHUO, J.; BECKER, B.; ZHONG, Y.; BEAUMONT, J. L.; DEROSA, M.; KISA, R. M.; BANERJEE, S.; STROBER, B. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s63, 2022. DOI: 10.25251/skin.6.supp.63. Disponível em: https://dermsquared.com/skin/article/view/1818. Acesso em: 20 sep. 2024.